CSL's desire to be an outstanding corporate citizen is integral to our work in making a positive contribution to the lives of patients with serious medical conditions who use our products.
It is also based on our significant research and development programs which aim to extend access to health care for patients with unmet medical needs.
Our strong commitment to the highest standards of corporate citizenship is underpinned by our Values, our Code of Conduct and our associated policy framework. Our people are educated about the way in which CSL's business is conducted through orientation programs as well as specific communication activities. Appropriate demonstration of the Values and Code of Conduct is integral to our performance management system.
Across the world, we contribute to improving the quality of life for patients with haemophilia. We work closely with Health Departments, the Blood Services, regulators, medical groups, patient communities and research and academic institutions to fulfil our ongoing commitment to original medical research and world class standards of patient care, education and support.
In Australia and New Zealand, we support excellence in haemophilia care and education as a Sustaining Patron of the Haemophilia Foundations of Australia and New Zealand, and we are an active supporter of the Inflammatory Neuropathy Support Group of Victoria Inc. and the Australia New Zealand Intensive Care Society Foundation and Clinical Trials Group.
In Asia, Latin America, the Middle East and Eastern Europe, we work with the haemophilia communities in the annual awarding of the ZLB Behring Grant. This year's grant, ‘Simple Things, Great Results', will be awarded to the top three project proposals submitted based on their likelihood of improving the quality of life of patients with haemophilia and von Willebrand disease in their local environment.
In the United States, ZLB Behring Choice is a program that offers resources and services to help families better manage the daily challenges of living with bleeding disorders.
We make wider contributions to the communities in which we operate through the ongoing development of relationships with our network of stakeholders. We recognise the interdependence that exists between our company and our customers, our people, our shareholders, our regulators, our suppliers and our communities and the value of aligning our efforts for mutual long term benefit.
Our Values
Superior Performance: We strive to be the best at what we do
Innovation: We seek better ways of doing things
Integrity: We are ethical and honest at all times
Collaboration: We work together to achieve better results
Customer Focus: We seek to understand and meet their needs
|
ZLB Behring’s strong support for patients has brought about the establishment of such innovative programs as Choice which offers a comprehensive range of resources and services designed to help families better manage the daily challenges of living with bleeding disorders.
Margaret Mary Conger (right) is a Choice Member Support Representative who helps patients to get the information and support that they need. Janet Reimund (left), a Program Specialist in haemophilia, is also closely involved in educational programs for patients.
ZLB Behring initiatives such as Gettin’ in the Game are designed to teach children with bleeding disorders the value of exercise - from the physical benefits to the emotional rewards. |
Back | Next
|
 |
| In the USA, The National Hemophilia Foundation and ZLB Behring have joined forces to offer an annual Junior National Championship in baseball and golf, another program to encourage children with bleeding disorders to get active and stay fit. |
 |
In the early 1990s, James Gerrand (above) contracted the immune-mediated nerve disorder known as chronic inflammatory demyelinating polyneuropathy (CIDP) for which he receives fortnightly infusions of CSL's Intragam® P. Continuing treatment has halted progression of the disease and enabled James to lead a relatively normal life.
The Australian Red Cross Blood Service provides plasma to CSL Bioplasma to produce Intragam® P, an intravenous immunoglobulin that is vital in the treatment of CIDP and Guillan-Barre Syndrome (GBS).
James is Director of a group in Victoria (Australia) that he started in 1992 to support CIDP and GBS patients, undertake research into the illness, and promote understanding of the condition. | |
